Wells Messersmith

Trials

Studies that name Wells Messersmith as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:41 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05167409 · Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

  University of Colorado, Denver · terminated · Microsatellite Stable Metastatic Colorectal Cancer · principal investigator
• Ph3
  NCT03781154 · Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors

  University of Colorado, Denver · completed · Colorectal Cancer · principal investigator
• Ph2
  NCT03542877 · Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

  Academic Thoracic Oncology Medical Investigators Consortium · completed · Colorectal Cancer · principal investigator
• Ph2
  NCT03038477 · A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

  University of Colorado, Denver · withdrawn · Pancreatic Cancer · principal investigator
• N/A
  NCT02955446 · Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

  University of Colorado, Denver · no longer available · Neoplasm, Desmoid Tumor · principal investigator
• Ph2
  NCT02723331 · Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

  Academic Thoracic Oncology Medical Investigators Consortium · completed · Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma · principal investigator
• Ph3
  NCT01360853 · Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

  Traws Pharma, Inc. · completed · Metastatic Pancreatic Adenocarcinoma · study chair
• Ph2
  NCT01232829 · Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

  National Cancer Institute (NCI) · completed · Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer · principal investigator
• Ph1/Ph2
  NCT00816777 · Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer

  Generic Devices Consulting, Inc. · terminated · Unresectable Metastatic Colo-rectal Cancer · principal investigator
• Ph2
  NCT00735917 · Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

  National Cancer Institute (NCI) · completed · Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer · principal investigator
• Ph2
  NCT00303927 · Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Pancreatic Cancer · study chair
• Ph1
  NCT00134069 · Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

  National Cancer Institute (NCI) · completed · Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer · principal investigator
• Ph1
  NCT00060411 · A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

  National Cancer Institute (NCI) · completed · Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 18:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
  UM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2020 to 2026 · $1,854,447 awarded in 2026
  Same name and institution; not confirmed by an ID
• Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients
  R01CA152303 · NCI · UNIVERSITY OF COLORADO DENVER · fiscal years 2010 to 2014 · $298,713 awarded in 2014
  Same name and institution; not confirmed by an ID
• Evaluation of Oral EGFR Inhibitors in Colorectal Cancer
  K23CA115500 · NCI · UNIVERSITY OF COLORADO DENVER · fiscal years 2005 to 2009 · $137,700 awarded in 2009
  Same name and institution; not confirmed by an ID
• Evaluation of Src Inhibition in Pancreas Cancer
  R21CA135622 · NCI · UNIVERSITY OF COLORADO DENVER · fiscal years 2008 to 2009 · $314,341 awarded in 2009
  Same name and institution; not confirmed by an ID
• BAY 43-9006 IN COMBINATION WITH CETUXIMAB AND IRINOTECAN
  M01RR000052 · NCRR · JOHNS HOPKINS UNIVERSITY · fiscal years 2007 · $38 awarded in 2007
  Same name and institution; not confirmed by an ID
• Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer
  R21CA117125 · NCI · UNIVERSITY OF COLORADO DENVER · fiscal years 2006 to 2007 · $246,308 awarded in 2007
  Grant number is on one of their registry trials

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• U01CA070095
  RePORTER returned no project for this number; it is shown as the registry gives it.
  Named on NCT01232829, NCT00134069, NCT00060411
• Cancer Research Training and Education Coordination
  P30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · fiscal years 2020 to 2026
  Named on NCT01232829
• Pathology Research Shared Resource
  P30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2020 to 2026
  Named on NCT00735917
• Cancer Chemical and Structural Biology
  P30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI James M. Berger · fiscal years 2020 to 2026
  Named on NCT00303927